EN DE
Watch Coherus BioSciences Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Coherus BioSciences Inc (CHRS) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Coherus BioSciences Inc stock $0.73, price $0.64, upside +13.8%, quality 30 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

CB Coherus BioSciences Inc logo Thin data Nov 10, 2026

Coherus BioSciences Inc

CHRS · US
Fairly valued, weak quality

The stock costs 12% less than our calculation considers fair.

Revenue last quarter +23% vs. a year ago.
Fair value $0.7296 · Fairly valued
Moderate debt
Mixed vs. peers (4/8)
Quality 30/100
Weak Growth (revenue 5y −38.4 %/yr in USD)
Negative free cash flow
Narrow moat 5/100
Thin data
Estimate
Watch Coherus BioSciences Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$18.99 $0.6409 Fair Value $0.7296 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.6409 – $18.99 · fair‑value band $0.5472 – $0.9120 · the $0.6409 price screens below the $0.7296 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Coherus BioSciences in your weekly email

Every Wednesday you see whether Coherus BioSciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.

Show moreShow less

The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma.

It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited.

The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.

Stock analysis

Coherus BioSciences Inc (CHRS) currently trades at $0.6409, while our estimate is $0.7296, so the stock looks roughly fairly valued today (gap 12.2%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.5472 (bear) to $0.9120 (bull), the price of $0.6409 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Coherus BioSciences Inc reported revenue of $42.2M in FY2025 versus $327M in FY2021, a compound −40.1%/yr. Reported net income was −$170M in FY2025.

Key figures

Market cap $126M Micro · P/S ratio 2.36 · EPS (TTM) $−1.25 · Return on equity −275% · Return on assets (EBIT) −43.8% (5-year average) · Operating margin −236% · Revenue (TTM) $53.6M · Revenue growth (YoY) +23.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (medium confidence).

What moves the price

The share trades about 74% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 14%, CHRS screens cheaper than that median.

Fair Value

Bear $0.5472 Fair Value $0.7296 Bull $0.9120
Price $0.6409 · Upside +13.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 14
Are margins and returns getting better?
Cashflow 30
Do the profits arrive as real cash?
Financial strength 49
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 29
How calm the share price moves, does not count
Price momentum 6
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 7 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−84.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−41.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−38.4%
Start year 2020 (pandemic). Over 10 years: +3.5% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
32.9% (2020) → −425.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch CHRS, get fair value alerts →

Compare Coherus BioSciences Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside +13.8% · Top 25%
Profitability
Return on assets −65.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 23.4% · Above median
Balance sheet
Debt / equity 0.61× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.07× · Cheaper than median
P/S (12 months) 2.36× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)52 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)70 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs CHRS
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs CHRS
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs CHRS
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs CHRS
argenx SE ARGX $971.55 $908.40 −7% vs CHRS
CSL Limited CSL A$201.68 A$181.40 −10% vs CHRS
Moderna, Inc MRNA $250.83 $158.70 −37% vs CHRS
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs CHRS
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs CHRS
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs CHRS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Coherus BioSciences Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Coherus BioSciences Inc Fair Value". https://www.fairvalue-calculator.com/stock/CHRS

Frequently asked questions

Is Coherus BioSciences Inc (CHRS) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.7296 versus a price of $0.6409, about +14% upside (fairly valued).
What is the fair value of CHRS?
Our estimate for Coherus BioSciences Inc is $0.7296 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.6409.
What is the quality score of CHRS?
Coherus BioSciences Inc has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Coherus BioSciences Inc (CHRS)?
Our calculated price target is the estimate of $0.7296 (as of Nov 10, 2026). Cautious scenario $0.5472, optimistic scenario $0.9120. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Coherus BioSciences Inc stock forecast for 2026?
Our estimate puts fair value at $0.7296, about +14% upside versus a price of $0.6409 (fairly valued). Cautious scenario $0.5472, optimistic scenario $0.9120. The calculation is refreshed regularly with new filings.
What is the revenue of Coherus BioSciences Inc (CHRS)?
Coherus BioSciences Inc reported trailing-twelve-month revenue of about $53.6M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Coherus BioSciences Inc (CHRS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Coherus BioSciences Inc it is $0.7296 per share (as of Nov 10, 2026), against a price of $0.6409.
Is Coherus BioSciences Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, CHRS trades below its calculated fair value: price $0.6409, fair value $0.7296, a gap of about +14% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CHRS?
No. The price is what the market pays today ($0.6409); the fair value is what the company's own numbers justify ($0.7296). For Coherus BioSciences Inc the two are $0.0887 per share apart. That gap is exactly why we show both numbers side by side.
How much is Coherus BioSciences Inc worth?
The market values Coherus BioSciences Inc at about $126M (market capitalisation, as of Nov 10, 2026). Per share that is $0.6409; our models calculate a fair value of $0.7296 per share.
What do the bullish and bearish scenarios say about CHRS?
Our models span a range for Coherus BioSciences Inc: cautious scenario $0.5472, base $0.7296, optimistic $0.9120 per share (as of Nov 10, 2026, price $0.6409). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Coherus BioSciences Inc (CHRS)?
Balance-sheet figures for Coherus BioSciences Inc (as of Nov 10, 2026): return on equity −275.2%, debt of 0.61 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is CHRS from its 52-week high?
Coherus BioSciences Inc trades at $0.6409, about 74% below its 52-week high of $2.51 and at the low of $0.6409 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.7296 is for.
Which stocks are comparable to Coherus BioSciences Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Coherus BioSciences Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $0.6409, calculated fair value $0.7296 (+14%), Quality Score 30/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Coherus BioSciences Inc currently trades 12% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Coherus BioSciences Inc (CHRS)?
The closing price on Nov 10, 2026 was $0.6409. Our estimate is $0.7296, about +14% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Coherus BioSciences Inc right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Coherus BioSciences Inc

How large is the market capitalisation of Coherus BioSciences Inc (CHRS)?
The market capitalisation of Coherus BioSciences Inc is $126M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Coherus BioSciences Inc (CHRS)?
The price-to-sales ratio of Coherus BioSciences Inc is 2.36 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Coherus BioSciences Inc (CHRS)?
Earnings per share at Coherus BioSciences Inc are $−1.25. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Coherus BioSciences Inc (CHRS)?
The return on equity (ROE) of Coherus BioSciences Inc is −275% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Coherus BioSciences Inc (CHRS)?
On an EBIT basis the return on assets of Coherus BioSciences Inc is −43.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Coherus BioSciences Inc (CHRS)?
The operating margin of Coherus BioSciences Inc is −236% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Coherus BioSciences Inc (CHRS)?
Revenue at Coherus BioSciences Inc is growing +23.4% versus a year earlier (3y avg −41.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Coherus BioSciences Inc (CHRS)?
Earnings per share at Coherus BioSciences Inc are growing −75.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Coherus BioSciences Inc (CHRS) generate?
The free cash flow of Coherus BioSciences Inc is −$139M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Coherus BioSciences Inc (CHRS) hold?
Coherus BioSciences Inc holds more cash than debt, $48.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Coherus BioSciences Inc in the live analysis

One click puts Coherus BioSciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.